Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Feb 22;483(7391):589-93.
doi: 10.1038/nature10910.

Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes

Affiliations
Free article

Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes

Jan J Molenaar et al. Nature. .
Free article

Abstract

Neuroblastoma is a childhood tumour of the peripheral sympathetic nervous system. The pathogenesis has for a long time been quite enigmatic, as only very few gene defects were identified in this often lethal tumour. Frequently detected gene alterations are limited to MYCN amplification (20%) and ALK activations (7%). Here we present a whole-genome sequence analysis of 87 neuroblastoma of all stages. Few recurrent amino-acid-changing mutations were found. In contrast, analysis of structural defects identified a local shredding of chromosomes, known as chromothripsis, in 18% of high-stage neuroblastoma. These tumours are associated with a poor outcome. Structural alterations recurrently affected ODZ3, PTPRD and CSMD1, which are involved in neuronal growth cone stabilization. In addition, ATRX, TIAM1 and a series of regulators of the Rac/Rho pathway were mutated, further implicating defects in neuritogenesis in neuroblastoma. Most tumours with defects in these genes were aggressive high-stage neuroblastomas, but did not carry MYCN amplifications. The genomic landscape of neuroblastoma therefore reveals two novel molecular defects, chromothripsis and neuritogenesis gene alterations, which frequently occur in high-risk tumours.

PubMed Disclaimer

References

    1. Nature. 2008 Oct 16;455(7215):930-5 - PubMed
    1. Cancer Res. 2005 Apr 15;65(8):3136-45 - PubMed
    1. J Clin Oncol. 2009 Mar 1;27(7):1026-33 - PubMed
    1. Nature. 2008 Oct 16;455(7215):967-70 - PubMed
    1. Crit Care. 2004 Oct;8(5):389-94 - PubMed

Publication types

MeSH terms

Substances

Associated data